Contineum Therapeutics Announces Publication Of Data In The Proceedings Of The National Academy Of Sciences On PIPE-307, Its M1 Receptor Selective Inhibitor For Relapse-Remitting Multiple Sclerosis
Portfolio Pulse from Benzinga Newsdesk
Contineum Therapeutics (NASDAQ:CTNM) announced the publication of preclinical data on PIPE-307, a selective M1 receptor inhibitor for relapse-remitting multiple sclerosis, in the Proceedings of the National Academy of Sciences. The data suggest PIPE-307 could be a first-in-class treatment.
July 31, 2024 | 9:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Contineum Therapeutics published promising preclinical data on PIPE-307, a selective M1 receptor inhibitor for multiple sclerosis, in a prestigious journal. This could position PIPE-307 as a first-in-class treatment, potentially boosting investor confidence.
The publication of promising preclinical data in a prestigious journal like PNAS can significantly boost investor confidence. PIPE-307's potential as a first-in-class treatment for multiple sclerosis could lead to increased interest and a positive short-term impact on CTNM's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100